FDA Approves Inspire® Upper Airway Stimulation (UAS) Therapy for Obstructive Sleep Apnea

Download as PDF

Fully Implanted Device Represents New Treatment Option for Patients Unable to Use CPAP

Minneapolis, Minn. – May 1, 2014 – Inspire Medical Systems, Inc. announced today that the U.S. Food
and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a
subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use
Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation
device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven,
convenient and easy to use.

Obstructive Sleep Apnea is a prevalent health issue affecting about 18 million Americans, according to
the National Sleep Foundation. Research shows that an individual with poorly managed OSA is at
increased risk for heart attack, stroke, weight gain, high blood pressure, heart failure and falling asleep
while driving. Sleep apnea can also be disruptive to one’s everyday activities causing depression, spousal
issues, irritability and daytime fatigue.

Current treatments for OSA include weight loss, CPAP, oral appliances and anatomy altering surgeries.
CPAP is the current standard of care for OSA management. It is often successful but recent studies have
shown that roughly half of all patients that start CPAP do not continue to consistently use it.

Inspire therapy is a fully implanted system consisting of three components: a small generator, a sensing
lead and a stimulation lead. The single external component is a small handheld Inspire sleep remote
used to turn the therapy on before bed and off upon waking. When activated, Inspire therapy senses
breathing patterns and delivers mild stimulation to key airway muscles, which keeps the airway open
during sleep. In contrast to other surgical options to treat sleep apnea, Inspire therapy does not require
removal or permanent alteration of facial or airway anatomy. As such, the procedure is less invasive and
should result in a shorter recovery time.

“The FDA approval of Inspire therapy represents a new era of choice for a subset of patients with
moderate to severe Obstructive Sleep Apnea who are unable to use CPAP,” said Tim Herbert, Inspire
Medical Systems president and CEO. “All of us at Inspire Medical Systems are committed to improving
the health and quality of life for these individuals with OSA, and we are excited to make this innovative
and much needed treatment available to patients and physicians.”

“This therapy represents a major advance in sleep apnea treatment for some patients who are unable to
use or tolerate CPAP therapy,” said Meir Kryger, MD, professor, Yale School of Medicine. “Patients with
moderate to severe OSA who are not on effective treatment are at an increased risk for cardiovascular
disease, accidents and death. There is a significant need for safe, effective and well-tolerated new
treatments in the sleep medicine field.”

Patients implanted with Inspire therapy who participated in the company’s STAR (Stimulation Therapy
for Apnea Reduction) pivotal clinical trial experienced a 68 percent reduction in apnea events, a 70
percent reduction in oxygen desaturation events, and significant improvements in daytime functioning
as measured by two validated questionnaires. These results were published in the January 9, 2014 issue
of the New England Journal of Medicine.

Inspire therapy will be commercially available to patients in the United States in the second half of 2014.

About Inspire Medical Systems
Inspire Medical Systems, based in Minneapolis, Minn., has developed the world’s first fully implanted
and FDA-approved neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA). The
Inspire system uses well established neurostimulation technologies and incorporates a proprietary
algorithm which stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire
was formed in 2007 when the technology, and a significant intellectual property portfolio, was
spun-out of Medtronic (NYSE: MDT). Inspire therapy is designed to reduce OSA severity and improve
quality of life for patients living with this challenging condition. Visit Inspire Medical Systems on the web
at www.inspiresleep.com.

Safety information for Inspire therapy is provided at www.inspiresleep.com. Inspire therapy is not for
everyone. Information at this site should not be used as a substitute for patients talking with their
doctor. Patients are encouraged to review this safety information and talk with their doctor about
diagnosis and treatment options.

Media contacts:
Helen Shik or Courtney Conery
MSLGROUP Boston
781-684-0770
InspireMedical@mslgroup.com